Sinocare shows digital health at CMEF

A glucose monitor is a sensor that tracks sugar levels through the day, like a weather app for blood sugar instead of a single finger-stick snapshot. Sinocare used the China International Medical Equipment Fair in Shanghai this week to show how it wants to connect those readings to home devices, clinics, and follow-up care. (prnewswire.com) The company said its display at the 93rd China International Medical Equipment Fair centered on a digital health system that links wearable devices, home monitoring tools, primary care, and hospital settings. The fair ran April 9-12, 2026, at the National Exhibition and Convention Center in Shanghai. (prnewswire.com) (cmef.com.cn) Sinocare put its continuous glucose monitoring line at the front of that pitch. The company said its sensors can provide up to 15 days of real-time readings and feed those readings into software for alerts, trend forecasts, and personalized interventions. (prnewswire.com) That matters in diabetes care because patients often move between hospital visits and long stretches of self-management at home. Sinocare has spent the past year promoting “whole-cycle” diabetes management, including hospital-wide glucose systems and post-discharge follow-up tools aimed at closing that gap. (sinocare.com) The company also used the fair to show that it is selling more than glucose meters. Its “Personal Palm Lab” lineup includes devices for glucose, blood pressure, uric acid, lipids, and ketones, all tied to data integration and automated risk alerts for home monitoring. (prnewswire.com) For clinics and pharmacies, Sinocare said it brought non-invasive diabetes risk screening called AGEscan, portable multi-function analyzers, and hemoglobin A1c testing systems. Hemoglobin A1c is the lab measure that shows average blood sugar over roughly three months, making it a standard tool for diagnosing and tracking diabetes. (prnewswire.com) Sinocare said it also signed partnerships with JD Health and Meituan Healthcare during the event. The company described those deals as a way to connect testing, repeat purchases, long-term management, and broader distribution through online and offline channels. (prnewswire.com) The company’s claims about device performance sit alongside a still-limited public research record. A 2025 open-access study of Sinocare’s iCan i3 continuous glucose monitor followed 36 people with type 1 or type 2 diabetes for up to 15 days and reported a mean absolute relative difference of 17.2%, with 77.1% of sensors lasting the full wear period. (link.springer.com) Sinocare said it is now in 187 countries and serves more than 25 million users, while describing itself as one of the world’s top four blood glucose meter companies. At CMEF, the message was that the next sales push is not just the sensor on a patient’s arm, but the software and service network built around it. (prnewswire.com)